TY - T1的急性呼吸窘迫综合征与肺泡巨噬细胞受损efferocytosis JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00829 -2021欧元六世- 58 - 3 y SP - 2100829 AU拉胡尔Mahida AU -亚伦·斯科特盟Dhruv帕尔克AU -塞巴斯蒂安·t·Lugg盟罗文·哈代非盟-加雷斯·g·拉威利盟Michael a . Matthay盟先生Naidu AU -加文·d·珀金斯盟David r . Thickett Y1 - 2021/09/01 UR - //www.qdcxjkg.com/content/58/3/2100829.abstract N2 -急性呼吸窘迫综合征(ARDS)是一种炎症性疾病的肺部,与脓毒症的主要病因学。尽管通风的发展策略,为中度到重度的ARDS死亡率仍然保持在40 - 46% [1]。ARDS与中性粒细胞涌入到肺泡。居高不下的中性粒细胞和低肺泡巨噬细胞(AM)在支气管肺泡灌洗(BAL)流体与更大的死亡率[2]。虽然早期的炎症肺泡环境ARDS最初延迟凋亡,最终这些中性粒细胞凋亡在肺泡[3]。高效efferocytosis AMs的凋亡中性粒细胞炎症[3]的决议是至关重要的。凋亡中性粒细胞可能积聚在ARDS由于缺陷是efferocytosis和/或不知所措efferocytosis能力,然后进行二次坏死,释放炎症介质进入肺泡空间[4]。这可能导致长期的炎症在ARDS。以前没有研究评估是efferocytosis ARDS;然而,monocyte-derived巨噬细胞(mdm) ARDS患者有受损efferocytosis [5]。 We investigated whether ARDS patients have impaired AM efferocytosis and increased alveolar neutrophil apoptosis.ARDS patients have decreased alveolar macrophage efferocytosis, which is associated with increased alveolar inflammation, and may contribute to worse clinical outcomes, including mortality. Upregulation of efferocytosis may offer a therapeutic strategy. https://bit.ly/2Q7REdM ER -